Your search returned 2 results

{0} results

{0} result

Relevance

Hogan Lovells Publications

Likely FDA impact of the government shutdown: Regulatory submission reviews, inspections, and research projects Focus On Regulation

27 December 2018

Blog Post

FDA Announces Policy for Unique Nonproprietary Names for Biologics and Biosimilars

31 August 2015

In a Federal Register notice, FDA announced its draft guidance, “Nonproprietary Naming of Biological Products,” in which the agency articulates the need “for biological products licensed...

Your search returned 2 results

Likely FDA impact of the government shutdown: Regulatory submission reviews, inspections, and research projects Focus On Regulation

FDA Announces Policy for Unique Nonproprietary Names for Biologics and Biosimilars

No results found for the matching keyword.